Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Præsentation
Citationsformater

Henrik Schmidt
Janet Brown
Ulrik Mouritzen
Peter Selby
Kirsten Fode
Svane, Inge Marie
Graham P Cook
David Hal Mollerup
Poul F Geertsen

This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).

Originalsprog	Engelsk
Tidsskrift	Clinical Cancer Research
Vol/bind	16
Udgave nummer	21
Sider (fra-til)	5312-9
Antal sider	8
ISSN	1078-0432
DOI	https://doi.org/10.1158/1078-0432.CCR-10-1809
Status	Udgivet - 1 nov. 2010

ID: 34133708